Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 2011

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 9
Chunk 2011
---
logy, and hematology/oncology.
Most recently, Ms. Landon served as Senior Vice President of Marketing and Communications at TherapeuticsMD with responsibility for the
branded portfolio, marketing insights, and corporate communications. Prior commercial leadership roles include VP Marketing at Radius
Health, VP Marketing at Sprout Pharmaceuticals (acquired by Valeant), Executive Director Women’s Health at Actavis Plc, and positions
of increasing responsibility in sales and marketing at Forest Labs, Abbott Labs, and Novartis. Ms. Landon holds an MBA from Silberman
College of Business at Fairleigh Dickinson University, and a Bachelor’s degree from Kean University.

61

Charles Allen is one of our directors
since July 11, 2023 and since February 5, 2014 has served as the Chief Executive Officer of BTCS Inc. (“BTCS”) and the Chairman
of the Board of BTCS since September 11, 2014. Mr. Allen is responsible for BTCS’ overall corporate strategy and direction. Since
December 2, 2022, Mr. Allen has been a director of Innovation1 Biotech Inc. Since January 12, 2018, Mr. Allen has been the Chief Executive
Officer of Global Bit Ventures Inc. (“GBV”). Since October 10, 2017, Mr. Allen has been a director of GBV. Mr. Allen has
extensive experience in business strategy and structuring and executing a variety of investment banking and capital markets transactions,
including financings, initial public offerings, and mergers and acquisitions. Prior to his work in the blockchain industry at BTCS, he
worked domestically and internationally on projects in technology, media, natural resources, logistics, medical services, and financial
services. He has served as a managing director at numerous boutique investment banks focused on advising and raising capital for small
and mid-size companies. Mr. Allen received a Bachelor of Science in Mechanical Engineering from Lehigh University and a Master of Business
Administration from the Mason School of Business at the College of William & Mary. The Board concluded that Mr. Allen’s background
and leadership experiences in the financial industry qualify him to be a member of the Board.

Cheryl Xu is one of our directors
since July 11, 2023 and until recently served as Biogen’s Vice President, Public Policy & Government Affairs since 2020. Ms.
Xu was PhRMA’s first Representative to China. Subsequently she started a consulting business in